



Conjunctival Ulceration Associated with Pembrolizumab

A 52-year-old woman with stage IIIc ovarian Mullerian duct carcinoma, administered pembrolizumab for 1 year, reported 3 months of redness and pain in her right eye. Her right eye had a visual acuity of 20/25 with ulcers on both the superior palpebral (A) and bulbar conjunctiva (B). Her left eye had a visual acuity of 20/20 with an ulcer only on the superior palpebral conjunctiva (C and D). Pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, can enhance immune response and may cause conjunctival and oral ulcers. Examination of palpebral conjunctiva in patients receiving this treatment is recommended. (Magnified version of Figure A-D is available online at www.aaojournal.org).

MENG WANG, MD^{1,2}

YONG ZHONG, MD^{1,2}

¹Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China; ²Beijing Key Laboratory of Fundus Diseases Intelligent Diagnosis & Drug/Device Development and Translation, Beijing, China
